DDInter419 DDInter899
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Clozapine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Clozapine {u} (Compound) resembles {v} (Compound) Prochlorperazine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azatadine
Clozapine {u} (Compound) binds {v} (Gene) CYP2D6
Clozapine {u} (Compound) upregulates {v} (Gene) ST3GAL5
Clozapine {u} (Compound) palliates {v} (Disease) bipolar disorder
Clozapine {u} (Compound) downregulates {v} (Gene) POLR2I
Clozapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clozapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Caffeine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Clozapine (Compound) resembles Trifluoperazine (Compound)
Clozapine (Compound) resembles Prochlorperazine (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Clozapine (Compound) binds CYP2D6 (Gene)
Clozapine (Compound) upregulates ST3GAL5 (Gene)
Clozapine (Compound) palliates bipolar disorder (Disease)
Clozapine (Compound) downregulates POLR2I (Gene)
Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clozapine may cause a minor interaction that can limit clinical effects when taken with Caffeine
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Trospium